Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985 Aug;20(2):93–99. doi: 10.1111/j.1365-2125.1985.tb05037.x

Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function.

A G Dupont, P Vanderniepen, A M Bossuyt, M H Jonckheer, R O Six
PMCID: PMC1400687  PMID: 2864051

Abstract

Chronic administration of nadolol has been reported to reduce blood pressure either without or with a concomitant fall of renal blood flow. We therefore studied the effects of nadolol 80 mg once daily on ambulatory blood pressure, renal and systemic haemodynamics in patients with mild to moderate essential hypertension. Ten patients took part in this randomized, double-blind, placebo-controlled, crossover study, each phase of which lasted 4 weeks. Nadolol significantly reduced ambulatory blood pressure and heart rate, but had no effect on blood pressure variability. Cardiac output was significantly reduced by nadolol and total peripheral resistance increased but without reaching statistical significance. Despite the fall in blood pressure and cardiac output, renal blood flow and glomerular filtration rate remained unchanged. The fraction of cardiac output reaching the kidneys rose significantly and renal vascular resistance was significantly reduced. Body weight, urinary sodium excretion and urine flow rate remained unchanged. We conclude that nadolol 80 mg once daily lowers ambulatory blood pressure in patients with mild to moderate hypertension without impairment of renal blood flow, indicating a redistribution of cardiac output to the kidneys. The mechanism of the renal vasodilator effect of nadolol remains to be determined.

Full text

PDF
93

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carrière S. Effect of norepinephrine, isoproterenol, and adrenergic blockers upon the intrarenal distribution of blood flow. Can J Physiol Pharmacol. 1969 Feb;47(2):199–208. doi: 10.1139/y69-034. [DOI] [PubMed] [Google Scholar]
  2. Clement D. L., Bogaert M. G., Pannier R. Effect of beta-adrenergic blockade on blood pressure variation in patients with moderate hypertension. Eur J Clin Pharmacol. 1977;11(5):325–327. doi: 10.1007/BF00566528. [DOI] [PubMed] [Google Scholar]
  3. Epstein M., Oster J. R. Beta-blockers and the kidney. Miner Electrolyte Metab. 1982 Nov;8(5):237–254. [PubMed] [Google Scholar]
  4. Epstein S. E., Braunwald E. The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease. Ann Intern Med. 1966 Jul;65(1):20–27. doi: 10.7326/0003-4819-65-1-20. [DOI] [PubMed] [Google Scholar]
  5. Fenyvesi T., Kállay K. The presence of beta-adrenergic receptors in the renal vascular bed. Acta Physiol Acad Sci Hung. 1970;38(2):159–166. [PubMed] [Google Scholar]
  6. Fitzgerald D. J., O'Callaghan W. G., McQuaid R., O'Malley K., O'Brien E. Accuracy and reliability of two indirect ambulatory blood pressure recorders: Remler M2000 and Cardiodyne Sphygmolog. Br Heart J. 1982 Dec;48(6):572–579. doi: 10.1136/hrt.48.6.572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Floras J. S., Jones J. V., Hassan M. O., Osikowska B., Sever P. S., Sleight P. Cuff and ambulatory blood pressure in subjects with essential hypertension. Lancet. 1981 Jul 18;2(8238):107–109. doi: 10.1016/s0140-6736(81)90296-8. [DOI] [PubMed] [Google Scholar]
  8. Frishman W. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 9. Nadolol: a new long-acting beta-adrenoceptor blocking drug. Am Heart J. 1980 Jan;99(1):124–128. doi: 10.1016/0002-8703(80)90322-1. [DOI] [PubMed] [Google Scholar]
  9. Goldberg L. I. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev. 1972 Mar;24(1):1–29. [PubMed] [Google Scholar]
  10. Gould B. A., Hornung R. S., Kieso H. A., Altman D. G., Cashman P. M., Raftery E. B. Evaluation of the Remler M2000 blood pressure recorder. Comparison with intraarterial blood pressure recordings both at hospital and at home. Hypertension. 1984 Mar-Apr;6(2 Pt 1):209–215. [PubMed] [Google Scholar]
  11. HINMAN A. T., ENGEL B. T., BICKFORD A. F. Portable blood pressure recorder. Accuracy and preliminary use in evaluating intradaily variations in pressure. Am Heart J. 1962 May;63:663–668. doi: 10.1016/0002-8703(62)90011-x. [DOI] [PubMed] [Google Scholar]
  12. Heel R. C., Brogden R. N., Pakes G. E., Speight T. M., Avery G. S. Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs. 1980 Jul;20(1):1–23. doi: 10.2165/00003495-198020010-00001. [DOI] [PubMed] [Google Scholar]
  13. Hollenberg N. K., Adams D. F., McKinstry D. N., Williams G. H., Borucki L. J., Sullivan J. M. beta-Adrenoceptor-blocking agents and the kidney: effect of nadolol and propranolol on the renal circulation. Br J Clin Pharmacol. 1979;7 (Suppl 2):219S–225S. doi: 10.1111/j.1365-2125.1979.tb04693.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Huttunen K., Huttunen N. P., Koivula A., Ahonen A., Puukka R. 99mTc-DTPA--a useful clinical tool for the measurement of glomerular filtration rate. Scand J Urol Nephrol. 1982;16(3):237–241. doi: 10.3109/00365598209179760. [DOI] [PubMed] [Google Scholar]
  15. KAIN H. K., HINMAN A. T., SOKOLOW M. ARTERIAL BLOOD PRESSURE MEASUREMENTS WITH A PORTABLE RECORDER IN HYPERTENSIVE PATIENTS. I. VARIABILITY AND CORRELATION WITH "CASUAL" PRESSURES. Circulation. 1964 Dec;30:882–892. doi: 10.1161/01.cir.30.6.882. [DOI] [PubMed] [Google Scholar]
  16. Krauss X. H., Schalekamp M. A., Kolsters G., Zaal G. A., Birkenhäger W. H. Effects of chronic beta-adrenergic blockade on systemic and renal haemodynamic responses to hyperosmotic saline in hypertensive patients. Clin Sci. 1972 Sep;43(3):385–391. doi: 10.1042/cs0430385. [DOI] [PubMed] [Google Scholar]
  17. Lee M. R. Dopamine and the kidney. Clin Sci (Lond) 1982 May;62(5):439–448. doi: 10.1042/cs0620439. [DOI] [PubMed] [Google Scholar]
  18. Mann S., Craig M. W., Altman D. G., Melville D. I., Raftery E. B. The effects of metoprolol on ambulatory blood pressure. Clin Sci (Lond) 1979 Dec;57 (Suppl 5):375s–377s. doi: 10.1042/cs057375s. [DOI] [PubMed] [Google Scholar]
  19. Nies A. S., McNeil J. S., Schrier R. W. Mechanism of increased sodium reabsorption during propranolol administration. Circulation. 1971 Oct;44(4):596–604. doi: 10.1161/01.cir.44.4.596. [DOI] [PubMed] [Google Scholar]
  20. O'Callaghan W. G., Laher M. S., McGarry K., O'Brien E., O'Malley K. Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients. Br J Clin Pharmacol. 1983 Oct;16(4):417–421. doi: 10.1111/j.1365-2125.1983.tb02187.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. O'Connor D. T., Barg A. P., Duchin K. L. Preserved renal perfusion during treatment of essential hypertension with the beta blocker nadolol. J Clin Pharmacol. 1982 Apr;22(4):187–195. doi: 10.1002/j.1552-4604.1982.tb02161.x. [DOI] [PubMed] [Google Scholar]
  22. O'Connor D. T., Preston R. A., Sasso E. H. Renal perfusion changes during treatment of essential hypertension: prazosin versus propranolol. J Cardiovasc Pharmacol. 1979 Nov-Dec;1(6 Suppl):S38–S42. [PubMed] [Google Scholar]
  23. Pavel D. G., Zimmer M., Patterson V. N. In vivo labeling of red blood cells with 99mTc: a new approach to blood pool visualization. J Nucl Med. 1977 Mar;18(3):305–308. [PubMed] [Google Scholar]
  24. Sannerstedt R., Conway J. Hemodynamic and vascular responses to antihypertensive treatment with adrenergic blocking agents: a review. Am Heart J. 1970 Jan;79(1):122–127. doi: 10.1016/0002-8703(70)90402-3. [DOI] [PubMed] [Google Scholar]
  25. Sullivan J. M., Adams D. F., Hollenberg N. K. beta-adrenergic blockade in essential hypertension: reduced renin release despite renal vasoconstriction. Circ Res. 1976 Oct;39(4):532–536. doi: 10.1161/01.res.39.4.532. [DOI] [PubMed] [Google Scholar]
  26. Tauxe W. N., Maher F. T., Taylor W. F. Effective renal plasma flow: estimation from theoretical volumes of distribution of intravenously injected 131-I orthoiodohippurate. Mayo Clin Proc. 1971 Aug;46(8):524–531. [PubMed] [Google Scholar]
  27. Textor S. C., Fouad F. M., Bravo E. L., Tarazi R. C., Vidt D. G., Gifford R. W., Jr Redistribution of cardiac output to the kidneys during oral nadolol administration. N Engl J Med. 1982 Sep 2;307(10):601–605. doi: 10.1056/NEJM198209023071007. [DOI] [PubMed] [Google Scholar]
  28. Volicer L., Liang C. S., Gavras H., Tifft C. P., Kershaw G. R., Gavras I., Griffith D. L., Vukovitch R., Brunner H. R. Effect of nadolol in treatment of hypertension. J Clin Pharmacol. 1979 Feb-Mar;19(2-3):137–147. doi: 10.1002/j.1552-4604.1979.tb02471.x. [DOI] [PubMed] [Google Scholar]
  29. Waal-Manning H. J., Hobson C. H. Renal function in patients with essential hypertension receiving nadolol. Br Med J. 1980 Aug 9;281(6237):423–424. doi: 10.1136/bmj.281.6237.423-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Waller D. G., Mihindukulasuriya J., Warren D. J. A comparison of the effects of intravenous propranolol and nadolol on the renal response to hypertonic saline infusion. Br J Clin Pharmacol. 1985 Jan;19(1):37–43. doi: 10.1111/j.1365-2125.1985.tb02610.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Warren S. E., O'Connor D. T., Cohen I. M., Mitas J. A. Renal hemodynamic changes during long-term antihypertensive therapy. Clin Pharmacol Ther. 1981 Mar;29(3):310–317. doi: 10.1038/clpt.1981.41. [DOI] [PubMed] [Google Scholar]
  32. Watson R. D., Stallard T. J., Littler W. A. Influence of once-daily administration of beta-adrenoceptor antagonists on arterial pressure and its variability. Lancet. 1979 Jun 9;1(8128):1210–1213. doi: 10.1016/s0140-6736(79)91896-8. [DOI] [PubMed] [Google Scholar]
  33. Weber M. A., Drayer J. I. Renal effects of beta-adrenoceptor blockade. Kidney Int. 1980 Nov;18(5):686–699. doi: 10.1038/ki.1980.186. [DOI] [PubMed] [Google Scholar]
  34. Wilkinson R., Pickering M., Robson V., Elliott R. W., Kerr D. N. The use of frusemide and propranool in the treatment of the hypertension of chronic renal disease. Scott Med J. 1974;19 (Suppl 1):25–32. doi: 10.1177/00369330740190S106. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES